Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.
IMPLANTATION OF THE PAS PORT VENOUS ACCESS DEVICE IN THE ONCOLOGY CLINIC BY A MEDICAL ONCOLOGIST (MEETING ABSTRACT)
Proc Annu Meet Am Soc Clin Oncol; 11:A1384 1992. Unique Identifier : AIDSLINE ICDB/92682113 Leming PD; Christ Hosp. Cancer Center, Cincinnati, OH 45219
Abstract:
The PAS Port (Pharmacia Deltec, Inc.) is a low-profile titanium venous access port designed to be implanted under the skin in the forearm and attached to a catheter threaded into the superior vena cava/atrium. Between August 1989 and November 1991, 78 attempts at placement using the Seldinger technique and minor surgical skills were done in an outpatient oncology clinic setting by a single medical oncologist. 70 insertions were successful (89.7%). In 4 cases the catheter would not thread, and in 4 cases venous access was not obtained. A prospective quality assurance data base was established including photographic follow-up of the surgical site. 77 patients (pts) were cancer pts needing venous access for chemotherapy. One pt had AIDS. Six ports were removed before death: 3 electively, 1 clotted subclavian vein, 1 catheter tip migration, 1 phlebitis of brachial/axillary vein. Of the original 78 pts, 29 (37%) have died. There were no port-related deaths. 22 pts died with their ports in place. 3 ports were removed before death, and 4 pts were unsuccessful attempts. The range of port use was 1-12 mo (mean 6.4 mo). 49 pts are still alive: 4 unsuccessful attempts, 3 removed and 42 remain in place. The range of port use is 8 days to 24 mo (mean 8.6 mo). The following complications were documented: major vein clotting 3 (3.9%), major phlebitis 1 (1.3%), minor phlebitis 3 (3.9%), drug infiltration 2 (2.6%), difficulty drawing blood 16 (21%), tip migration 1 (1.3%) and clotted port 1 (1.3%). There were no documented infectious complications. Pt acceptance was uniformly excellent. The PAS Port device can be safely implanted by a medical oncologist in the outpatient clinic setting and offers a viable alternative to standard venous ports.
Keywords: Acquired Immunodeficiency Syndrome/DRUG THERAPY Antineoplastic Agents/ADMINISTRATION & DOSAGE Antiviral Agents/ADMINISTRATION & DOSAGE *Catheters, Indwelling/ADVERSE EFFECTS Medical Oncology/MANPOWER Neoplasms/DRUG THERAPY ABSTRACT 921230
M92C5375
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.
